LEO Pharma to Showcase Its Broadest Ever Scientific Program at EADV 2026

For best results when printing this announcement, please click on link below: LEO Pharma to Showcase Its Broadest Ever Scientific Program at EADV 2026 LEO Pharma will present 28 accepted abstracts at the 2026 European Academy of Dermatology and Venereology Congress, taking place from 30 September to 3 October in Vienna, Austria.

The EADV 2026 program reflects the strength and breadth of LEO Pharma’s portfolio, showcasing what’s now and what’s next in medical dermatology with new evidence across nine disease areas, six routes of administration and nine modes of action; including biologic injectables, topical formulations, and covering data across established dermatology brands and new innovation. The program underscores LEO Pharma’s continued commitment to advancing medical dermatology through evidence that addresses both highly prevalent chronic skin diseases and complex or rare, hard-to-treat conditions with significant unmet needs.

LEO Pharma A/S, a global leader in medical dermatology, will present a broad scientific program at the 35th European Academy of Dermatology and Venereology Congress, held from September 30 to October 3, 2026 in Vienna, Austria. “At EADV 2026, we are proud to share a strong body of scientific evidence that reflects the breadth of our portfolio and our ambition to keep advancing medical dermatology while showcasing what’s now and what’s next,” said Jacob Thyssen, Chief Scientific Officer, LEO Pharma. ” A key focus of the program is tralokinumab, with eight original abstracts accepted, including two oral presentations and six ePosters.

New real-world TRACE data will highlight tralokinumab’s impact in patients with moderate-to-severe atopic dermatitis involving high-burden areas such as head & neck, hands, feet and genitals, alongside associated changes in quality of life. LEO Pharma will also present six delgocitinib abstracts, including one oral presentation and five ePosters, further expanding the evidence base in chronic hand eczema. The program includes real-world data from the German REACHED study and an oral presentation on health-related quality of life in adolescents treated with delgocitinib cream.

“Across atopic dermatitis and chronic hand eczema, our EADV 2026 data underline the importance of evidence that goes beyond traditional clinical endpoints,” said Sophie Lamle, Chief Development Officer, LEO Pharma. ” Looking further ahead, LEO Pharma will present first-in-human Phase 1 data for LEO-158968, a novel anti-IL-1RAcP monoclonal antibody that demonstrated a clear PK/PD relationship and strong pharmacological activity. The program includes four spesolimab abstracts covering generalized pustular psoriasis and pyoderma gangrenosum, with data on long-term efficacy, flare management and unmet needs in diagnosis and treatment.

LEO Pharma will also present new brodalumab data in plaque psoriasis, including comparative analyses in patients with overweight or obesity. The full roster of new and encore abstracts(1-28) at the 2026 EADV congress includes: Tralokinumab Full title Authors ID & Format Initiating biologics in atopic dermatitis: Global practices and April W. Armstrong, Andrew E. Pink, Joe Gorelick, Mariateresa Rossi, Magdalena AS-2446 Oral presentation Session FC01: 08:40—08:50, Thu 1 Oct 2026, Hall N recommendations from the AMAZE project Trzeciak, Mette Deleuran, Hyun Jung Kim, Saeko Nakajima, Vimal H.

Prajapati Real-world use of tralokinumab in patients with atopic dermatitis involving April W. Armstrong, Andrew E. Pink, Ahmed Ameen, Marni Wiseman, Adrian AS-1845 Oral presentation Session FC02: 10:15—10:25, Thu 1 Oct 2026, Hall N high-burden areas: Effectiveness and impact on quality of life in the Rodriguez, Alessandra Narcisi, Audrey Nosbaum, Teodora Festini, Kavita Kapoor, prospective, non-interventional 12-month TRACE study Frank Vinther, Ida Vittrup, Diamant Thaci Real-world characterization of early and delayed responses to tralokinumab April W.

Armstrong, Jose Juan Pereyra Rodriguez, Ahmed Ameen, Elena Pezzolo, AS-1852 ePoster P1604 among patients with atopic dermatitis: Results from the prospective, Teodora Festini, Frank Vinther, Ida Vittrup, Diamant Thaci international, non-interventional 12-month TRACE study Determination of a head and neck response criterion as an optimal treatment Raj Chovatiya, Simone Ribero, Andrew Blauvelt, Diamant Thaçi, Andrew E.

Pink, AS-1949 ePoster P1609 target for patients with atopic dermatitis with head and neck involvement Chih-ho Hong, Sebastien Barbarot, Rie von Eyben, Peter van Iperen, John Stinson, Stephan Weidinger Tralokinumab monotherapy improves atopic dermatitis severity in patients with Benjamin Ehst, H. Chih-ho Hong, Leon Kircik, Francisco J. Navarro-Trivino, AS-429 ePoster P1575 moderate-to-severe atopic hand eczema Marie Tauber, April W.

Armstrong, Frida Emanuelsson, Anne Louise Svendsen, Ann-Marie Tindberg, Stephan Weidinger Tralokinumab monotherapy rapidly improves sleep, daily functions, and Sebastian Volc, Irina Turchin, Marie Tauber, Richard Woolf, Maria Czubek, AS-1844 ePoster P1595 health-related quality of life in patients with atopic dermatitis and Thomas Rustemeyer, Ann-Marie Tindberg, Sylwia Cholewinska, Frank Vinther, moderate-to-severe hand involvement Benjamin Ehst Tralokinumab provides early and sustained improvements in head and neck atopic Raj Chovatiya, Simone Ribero, Andrew Blauvelt, Amy S Paller, Chih-ho Hong, AS-1046 ePoster P1581 dermatitis among adolescents with moderate-to-severe disease Anthony Bewley, Andrew E Pink, John Stinson, Rie von Eyben, Peter van Iperen, Andreas Wollenberg Long-term efficacy and safety of tralokinumab in adolescents aged 12—17 Amy S Paller, Carsten Flohr, Michael Cork, Anthony Bewley, Andrew Blauvelt, H.

AS-212 ePoster P1513 years with moderate-to-severe atopic dermatitis Chih-Ho Hong, Shinichi Imafuku, Marie-Louise A Schuttelaar, John Stinson, Peter van Iperen, Rie von Eyben, Andreas Wollenberg Delgocitinib Full title Authors ID & Format Real-world effectiveness of delgocitinib cream in adults with moderate to Sonja Molin, Christian Apfelbacher, Laura Burgahn, James Greig, Rie von Eyben, AS-2192 ePoster P1613 severe Chronic Hand Eczema: interim analysis after 8 weeks of treatment in the Khusru Asadullah German REACHED study Delgocitinib cream provides rapid improvements in itch and pain symptoms in Sonja Molin, Francisco J. Navarro-Triviño, Ziad Reguiai, F.

Elcin Darendeli, AS-1702 ePoster P2395 adolescents with moderate to severe chronic hand eczema: Results from DELTA Eydna Didriksen Apol, Line Conradsen Hiort, Henrik Thoning, Anthony Bewley, TEEN Amy Paller Treatment with delgocitinib cream improves health-related quality of life in Sonja Molin, Diana Rubel, Francisco J. Navarro-Triviño, Ziad Reguiai, Sofie AS-1174 Oral presentation Session FC02: Free Communication 2: Atopic adolescents with moderate to severe chronic hand eczema: Results from DELTA De Schepper, James Halpern, Danielle Marcoux, John Su, Paweł Brzewski, F.

dermatitis/Eczema, Thu 1 Oct, 11:25—11:35, Hall N TEEN; a randomized, double-blind, vehicle-controlled phase 3 trial Elcin Darendeli, Eydna Didriksen Apol, Henrik Thoning, Jeff Yu, Lawrence F. Eichenfield Delgocitinib cream reduces patient-reported disease severity in adults with Anthony Bewley, Linda Stein Gold, James Greig, Kira Hyldekaer Janstrup, Sven AS-1236 ePoster P1525 moderate to severe Chronic Hand Eczema: pooled analysis of the Phase 3 DELTA 1 Malte John and DELTA 2 trials ENCORE HRQoL and Work Productivity Improvements with Topical Delgocitinib vs Andrea Bauer, Timo Buhl, Richard Woolf, James Greig, Jenny M.

Norlin, Henrik AS-1951 ePoster P1608 Oral Alitretinoin in Chronic Hand Eczema: Phase 3 DELTA FORCE Results Thoning, Ana Maria Gimenez-Arnau ENCORE Sustained Health-Related Quality of Life improvements with April W. Armstrong, Linda Stein Gold, Andrea Bauer, James Greig, Jenny M.

AS-595 ePoster P1576 Delgocitinib 20 mg/g Cream in Chronic Hand Eczema — Results from the Phase 3 Norlin, Henrik Thoning, Tove Agner Open-Label Extension DELTA 3 Trial Spesolimab Full title Authors ID & Format Healthcare professional (HCP) perception of pyoderma gangrenosum (PG): Alavi A, Dini V, Kirsner RS, Sequeira R, Ortega Loayza AG AS-534 ePoster P0894 Real-world insights of unmet needs and treatment goals ENCORE Long-term disease control with subcutaneous spesolimab in GPP Krueger JG, Lebwohl MG, Morita A, Burden AD, Anadkat AJ, Reardon J, Tang M, AS-525 ePoster P0881 patients with or without IL-36RN mutation.

Results from the EFFISAYIL ON study Thoma C, Gudjonsson JE ENCORE Long-term (≥3 year) efficacy and safety of subcutaneous spesolimab Gudjonsson JE, Navarini AA, Langley RG, Krueger JG, Mostaghimi A, Burden AD, AS-530 ePoster P0879 for treatment of generalized pustular psoriasis: Results from the EFFISAYIL Tang M, Reardon J, Thoma C, Morita A program ENCORE Intravenous spesolimab for (re)treatment of generalized pustular Gordon K, Navarini AA, Choon SE, Warren RB, Anadkat MJ, Tang M, Reardon J, AS-532 ePoster P0893 psoriasis flares in patients receiving subcutaneous spesolimab: Results from Thoma C, Lebwohl MG the 5-year, open-label, EFFISAYIL ON extension study Early Portfolio Full title Authors ID & Format LEO 158968, a Novel Anti-IL-1RAcP Monoclonal Antibody, Demonstrates a Clear Tristan Pascart, Anne-Marie Schmitt, Victor Laurent, Gauthier Marchasson, AS-2307 ePoster P1750 PK/PD Relationship and Strong Pharmacological Activity in Patients: Results Dorothée Brzyski, Mie Larsen Broberg, Jens Strodl Andersen, Frank Vinther, from a Phase 1 Program Petra Arlert, Thomas Quémeneur, Takashi Satoh, Lars E.

French Development and content validity testing of two new Patient Reported Outcome Andrew E.

Pink, Robert Bissonnette, Jason Hawkes, Joanna Narbutt, Rotraut AS-2215 ePoster P2316 (PRO) instruments in Palmoplantar Pustulosis (PPP) Mößner, Petra Arlert, Dale Chandler, Laura Grant, Megan Mayhew, Henrik Meincke, Anne Marie Schmitt, Matthias Augustin Core Brands Full title Authors ID & Format Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Brodalumab Matteo Megna, Veena Lim, Emily Foreman, Corinne Le Reun, Marie Jablonski AS-1924 e-Poster P2610 and Secukinumab in the treatment of Patients with Moderate-to-Severe Plaque Bernasconi, Sascha Gerdes Psoriasis Weighing 90 kg or More Real world response to Cal/BD aerosol foam long-term maintenance treatment in Efterpi Zafeiriou, Efstathios Rallis, Georgios Gaitanis, Efstathios Gourvelos, AS-1025 ePoster P1199 patients with plaque psoriasis: an observational, prospective study in Greek John Katsantoni, Alexandra Kourouklidou, Natalia Rompoti, Dimitrios Sgouros, clinical setting (the STABILITY study) Irene Stefanaki, Eleftheria Tampouratzi, Athanasios Chaniotis, George Pesiridis, Efthymios Stathatos, Alexander Stratigos Brodalumab demonstrates rapid effectiveness in patients with Efterpi Zafeiriou, Aimilios Lallas, Despina Arnaoutoglou, Pantelis Aronis, AS-1018 e-Poster P1198 moderate-to-severe plaque psoriasis: short-term results from the Greek Alexandros Drosos, Maria Pizimola, Nikolaos Rotsiamis, Irene Stefanaki, REALITY-1 non-interventional study Athanasios Chaniotis, George Pesiridis, Efthymios Stathatos, Alexander Katoulis, Sophia Georgiou ENCORE Topical Calcineurin Inhibitors and Malignancy Risk: A Critical Review Andreas Wollenberg, Alejandro Arana, Michael J.

Cork, Mette Deleuran, Regina AS-2229 e-Poster P0912 Fölster-Holst, H. (44,45) About Anzupgo(®) (delgocitinib) Cream Anzupgo® cream is a topical non-steroidal pan-Janus kinase (JAK) inhibitor for the treatment of moderate to severe CHE in adults. (46) Anzupgo® is approved in the European Union, United Kingdom, Switzerland, Canada, Australia, South Korea, Saudi Arabia, Macau and the United Arab Emirates for the treatment of moderate to severe Chronic Hand Eczema (CHE) in adults for whom topical corticosteroids are inadequate or inappropriate. S.

for moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. S. , Ltd. owns the rights.

(48-50) Adtralza® / Adbry® is approved for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy in the European Union, United States, Canada, the United Arab Emirates and South Korea. Adtralza® is approved for use in adults with moderate to severe atopic dermatitis in Switzerland, Saudi Arabia and Japan. Adtralza is also approved for adolescents in Saudi Arabia.

About Spevigo® Spevigo® is a humanized, selective antibody that specifically blocks activation of the IL-36R, a signalling pathway within the immune system shown to be involved in the pathogenesis of several autoinflammatory diseases, including GPP.